P01.136 Safety and adverse event profile of tumor treating fields in elderly patients - a post-market surveillance analysis

摘要

BackgroundTumor Treating Fields (TTFields) are an established modality for glioblastoma (GBM) treatment administered through the portable Optune system. The efficacy of Optune in newly diagnosed GBM was previously demonstrated in the EF-14 phase 3 trial (n=695). Optune plus temozolomide significantly improved survival in all patient subgroups compared to temozolomide alone, which included those patients ≥ 65 years of age (median OS: 17.1 vs 13.7 months). Here, we report post-marketing surveillance data from elderly patients treated with Optune.